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Abstract 
Background: Crush syndrome (CS) is characterized by ischemia/reperfusion (I/R)-induced 
rhabdomyolysis and the subsequent onset of systemic inflammation. CS is associated with a 
high mortality, even when patients are treated with conventional therapy. We hypothesized 
treatment of lethal CS rat model with dexamethasone (DEX) have therapeutic effects on the 
laboratory findings and clinical course and outcome. 
Methods: To create a CS model, anesthetized rats were subjected to bilateral hind limb 
compression with rubber tourniquets for 5 hours, and randomly divided into 3 groups: 
saline-treated CS, and low (0.1 mg/kg) and high doses (5.0 mg/kg) of DEX-treated CS groups. 
Saline for the CS group or DEX for the DEX-treated CS groups was intravenously 
administered immediately before reperfusion. Under continuous monitoring and recording of 
arterial blood pressures, blood and tissue samples were collected for histological and 
biochemical analysis at designated time period before and after reperfusion. 
Results: Under continuous monitoring and recording of arterial blood pressures, blood and 
tissue samples were collected for histological and biochemical analysis at designated time 
period before and after reperfusion. Ischemic compression of rat hind limbs reduced the 
nitrite content in the crushed muscle, and the subsequent reperfusion induced reactive oxygen 
species-mediated circulatory collapse and systemic inflammation, finally resulting in a 
mortality rate of 76% by 48 hours after reperfusion. A single injection of high-dose DEX 
*Abstract
immediately before reperfusion activated endothelial nitric oxide synthase (eNOS) by 
sequential phosphorylation through the non-genomic phosphoinositide 3-kinase 
(PI3K)-Akt-eNOS signaling pathway. DEX also exhibited anti-inflammatory effects by 
modulating pro- and anti-inflammatory mediators, consequently suppressing 
myeloperoxidase activities and subsequent systemic inflammation, showing a complete 
recovery of the rats from lethal CS. 
Conclusion: These results indicate that high-dose DEX reduces systemic inflammation and 
contributes to the improved survival rate in a rat CS model. 
Level of Evidence: Level Ⅰ 
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Introduction 
Crush syndrome (CS) is a serious medical condition characterized by hypovolemic 
circulatory shock, hyperkalemic metabolic acidosis, and acute myoglobinuric renal failure 
and is frequently observed after traumatic events such as earthquakes, landslides, and vehicle 
accidents
1
.
Currently recommended treatment for CS involves early aggressive volume repletion using 
normal saline and alkaline diuresis with bicarbonate and mannitol, combined with the 
correction of hyperkalemia
1
. When such patients demonstrate acute myoglobinuric renal
failure that is severe enough to produce refractory hyperkalemia, acidosis, and uremia, 
transfer to a hospital and hemodialysis are urgently indicated. Although the use of 
antioxidants and free-radical scavengers has emerged as a promising new approach for the 
treatment of acute kidney injury
2
 and systemic inflammation, controlled studies evaluating
their efficacy are currently lacking. At present, no satisfactory treatment has been established 
for CS because these conventional managements provide only symptomatic management, not 
treatment of the underlying mechanism. 
The most important mechanism causing CS-related mortality is ischemia/reperfusion 
(I/R)-induced rhabdomyolysis and the subsequent onset of reactive oxygen species 
(ROS)-mediated systemic inflammation
3,4
, we therefore directed our therapeutic attention to
an old drug, glucocorticoid, which has recently been attracting new research attention due to 
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the recent recognition of its anti-inflammatory action in a receptor-dependent, but 
transcription-independent, manner (non-genomic pathway).Recent studies have reported 
beneficial effects of glucocorticoids in the treatment of experimental I/R injury due to 
myocardial infarction
5
, cerebral stroke
6
, and kidney damage
7
 through the non-genomic
pathway, in which glucocorticoid receptor-mediated signaling phosphorylates 
phosphoinositide 3-kinase (PI3K) and subsequently activates Akt and endothelial nitric oxide 
synthase (eNOS)
8
. However, there has so far been no experimental evidence of the potential
therapeutic benefits of glucocorticoid administration for CS. 
We previously reported the development of a practical animal model for crush injury using 
simple rubber tourniquets compressing the bilateral hind limbs of the rat for 5 hours
9
. This
model has a similar clinical appearance to lethal human CS, with a high mortality due to 
rhabdomyolysis, serious arrhythmia with hyperkalemia, circulatory shock, and remote organ 
failure, including lung edema and acute renal failure. Using this model, in the present study 
we investigated the effects of dexamethasone (DEX) on the clinical course and outcome of 
CS, and showed complete recovery of the rats from lethal crush injury. We also provide 
evidence of the possible mechanism underlying the anti-I/R injury effects of DEX. Moreover, 
this study provides a simpler and more useful first-aid treatment for CS, which should be 
implemented as soon as possible in the field of disaster medicine. 
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MATERIALS AND METHODS 
Animal model 
  Male Wistar rats weighing 250–300 g obtained from Kiwa Laboratory Animals 
(Wakayama, Japan) were housed in a room maintained at a temperature of 23 ± 3 °C and a 
relative humidity of 55 ± 15% with a 12-h light-dark cycle, with free access to food and water. 
All animal experiments were conducted according to the guidelines for animal use approved 
by the Life Science Research Center of Josai University (approval reference number: 
H23015). Anesthesia was induced by the intraperitoneal injection of pentobarbital sodium (50 
mg/kg body weight). The body temperature was maintained by a heating lamp during the 
experiment. The CS model was generated as reported previously
9
. In brief, a rubber
tourniquet that applied by wrapping five turns around a metal cylinder under a 2 kg load, and 
the end of the band was glued. After a given period of time, the compression was released by 
cutting and removing the tourniquet. 
Experimental design 
The animals were randomly assigned to four groups. Three CS groups were subjected to 
hind limb compression for 5 hours
9
 (SDC Method 1), followed by the infusion of 100 μL of
normal saline (CS control group: n=44) or the infusion of 100 μL of different doses of 
dexamethasone 21-phosphate disodium salt (DEX, SIGMA-ALDRICH) (0.1 or 5.0 mg/kg of 
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7 
DEX, CS+DEX-0.1: n=29 and CS+DEX-5.0: n=25, respectively) immediately before 
reperfusion. A sham group (n=25) serving as a control underwent the same procedures as all 
the three CS groups except for the compression and decompression with rubber tourniquets. 
All rats were placed under anesthesia (intraperitoneal injection of pentobarbital sodium, 50 
mg/kg body weight) during the 5 h compression period, then were allowed to recover and 
were kept without intravenous fluid solution but with oral free access to food and water until 
they were killed for the sampling of blood and tissues at the designated time periods. 
  In a separate experiment, four groups of rats (CS control group: n=29; sham and 
CS+DEX-5.0 groups: n=10; and CS+DEX-0.1 group: n=14) were prepared and observed for 
48 h after reperfusion to determine the survival rates. 
  To compare the therapeutic effects of DEX with the conventional therapies such us early 
fluid resuscitation and/or correction of acidosis, another set of experiment was also 
performed using the CS rats treated with fluid resuscitation (30mL/kg/hr, starting 
immediately after reperfusion for first 3 hours) of saline or bicarbonated Ringer's solution 
(BICARBON
○R
, Ajinomoto Pharmaceutical Co. Ltd. Tokyo). 
Recording and analysis of the mean arterial pressure 
  At the designated time period after reperfusion, each group was re-anesthetized with an 
intraperitoneal injection of pentobarbital sodium (50 mg/kg body weight) to record the mean 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
 
arterial blood pressure (MAP). The femoral artery was cannulated with a polyethylene 
catheter (INTERMEDIC
TM
 PE-50 tubing; Becton Dickinson and Company, Sparks, MD) 
connected to a pressure transducer. The blood pressures were amplified, displayed, and 
recorded via a PowerLab™ data acquisition system (AD Instruments, UK).  
 
Blood and tissue sampling  
  Blood samples from each group were obtained at one, three, six, and 24 h after reperfusion 
(n=3). The analyses of the pH, PO2, PCO2, HCO3
-
, and base excess (BE) of the arterial blood 
obtained from the femoral artery were performed using a blood gas analyzer (i-STAT300F
®
, 
FUSO Pharmaceutical Industries, Ltd., Osaka, Japan). Venous blood from the postcaval vein 
was sampled and centrifuged to measure the plasma levels of potassium ion (K
+
), blood urea 
nitrogen (BUN), creatinine, creatine phosphokinase (CPK), and lactate dehydrogenase (LDH) 
(measurements were performed by SRL Inc., Tokyo, Japan). Tissue samples from the 
gastrocnemius muscles, kidneys, and lungs were subjected to a histological analysis, 
measurement of the MPO activity, nitrite or nitrate level, and a Western blot analysis. 
 
Nitrite and nitrate concentrations in the muscle and plasma 
  The nitrite concentrations in muscle were measured using a dedicated HPLC system 
(ENO-20; Eicom, Kyoto, Japan) according to the method previously reported
3
.  
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Plasma levels of interleukin 6 and 10  
 The plasma levels of interleukin (IL)-6 and 10 (Rat IL-6 and 10 ELISA kit; Endogen, Inc) 
were measured by ELISA according to the manufacturer’s instructions. 
 
Western blot analysis 
 According to the method previously reported 
6
, the muscle tissue samples obtained from 
the rats were homogenized and centrifuged Muscle lysates were applied to SDS-PAGE using 
antibodies against eNOS, P-eNOS (Santa Cruz Biotechnology), Akt, P-Akt, p85, P-p85, 
iNOS (Cell Signaling), HO-1 (Thermo), and α-tubulin (Cell Signaling). The bound antibodies 
were visualized using the ECL chemiluminescence detection system (SuperSignal West Dura 
Extended Duration Substrate, Pierce) with HRP-conjugated secondary antibodies (Pierce). 
The band intensity was quantified using a Bio Imaging System, with the Gene Snap and Gene 
Tools software programs (Syngene Bio Imaging, Cambridge, USA). Control of the protein 
loading and transfer was conducted by determining the α-tubulin levels. 
 
Determination of ROS 
ROS production in the injured gastrocnemius muscle was determined by measuring the 
thiobarbituric acid reactive substances (TBARS) according to the method previously reported 
by Uchiyama et al.
10
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Histology and MPO activity 
  For the histological evaluations, tissue samples were collected 3 hours after reperfusion, 
then fixed in 10% formalin and embedded in paraffin wax. The sections were then cut and 
stained with hematoxylin and eosin, and were carefully examined microscopically (SDC 
Method 2). MPO activities in the muscle tissues were measured according to the technique 
described by Murata et al
9
. 
 
Statistical analysis 
  The results are expressed as the means ± the standard error of the mean (SEM). ANOVA 
was used for each of the variables to assess the differences between each group, and Tukey’s 
honestly significant difference test or the Tukey-Kramer test was used to compare the results 
between groups. Survival curves were calculated by the Kaplan-Meier method, with the level 
of significance set at p< 0.05, and survival was compared by a log-rank test. Differences 
were considered to be significant for values of p< 0.05. 
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RESULTS 
Survival rates  
In the present study, crush injury gradually decreased the survival rate in the CS control 
group, with the survival rate decreasing to 76%, 45%, and 28% at 3, 6, and 18 hours after 
reperfusion, respectively, then finally to 24% by 48 hours after reperfusion (SDC Figure 1). 
On the other hand, the treatment of CS rats with CS+DEX-0.1 group significantly improved 
the survival rate until 18 hours after reperfusion, although it ultimately ended in failure 48 
hours after reperfusion, with a final mortality rate similar to the CS control group. However, 
to our surprise, CS+DEX-5.0 group saved all CS rats, and maintained a 100% survival rate 
over the 48-hour experimental period (SDC Figure 1). On the other hand, the conventional 
therapies of fluid resuscitation with saline and bicarbonated Ringer's solution for this CS 
models (30% and 60% of survival rates by 48 hours after reperfusion, respectively) appear to 
be inferior to DEX treatment in survival rate (SDC Figure 2).  
 
Effects of DEX on plasma biochemical markers, mean arterial pressure and blood gas  
As shown in Table 1, the CS control rats showed significant increases in the markers of 
rhabdomyolysis, such as CPK, K
+
, and LDH in the plasma as early as one hour after 
reperfusion, with each peak value observed at 3, 6, and 24 hours after reperfusion, 
respectively. In Table 2, the CS control rats showed a significantly decreased MAP 
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throughout the 24-hour experimental period, which consequently induced metabolic acidosis 
shown in the arterial blood gas analysis (pH, base excess, HCO3
-
 and lactate). However, DEX 
remarkably suppressed not only rhabdomyolysis, but also the subsequent hypovolemic 
hypotension in a dose-dependent manner (Table 2). In addition, the circulatory improvement 
associated with DEX also decreased the plasma levels of renal damage markers, such as 
creatinine and BUN, which began to increase at three hours after reperfusion in the CS 
control rats (Table 1). More beneficial effects of DEX were also shown than the conventional 
therapies of fluid resuscitation on plasma biochemical markers, MAP and blood gas (SDC 
Table 1 and 2). 
 
DEX-induced NO production through the non-genomic signaling pathway and the 
subsequent reduction of ROS production  
We examined the non-genomic activation of the PI3K-Akt-eNOS signaling pathway in 
injured muscle by DEX. DEX exhibited a tendency to increase the phosphorylation of the 
regulatory p85 subunit of PI3K compared with untreated CS rats in the early phase (0.5-3 h) 
after reperfusion (Figure 1A), and CS+DEX-5.0 group significantly activated and amplified 
the Akt phosphorylation and subsequent eNOS phosphorylation at 1 and 3 hours after 
reperfusion (Figures 1B and C). However, it has been difficult to evaluate the NO production 
in injured muscle. Because of the difficulty associated with evaluating the biological NO 
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production directly using in vivo studies, we instead measured the muscle levels of nitrite, a 
stable NO oxidation product indicative of the level of NO production. Activated eNOS 
produced NO and resulted in increased levels of nitrite in the muscle compared with that in 
the CS control rats at one hour after reperfusion (Figure 2A). Despite the increased eNOS 
phosphorylation (P-eNOS Western blots are shown in Figure 1C) by DEX, the total eNOS 
protein expression was not quantitatively different among the groups (normalized by 
α-tubulin, SDC Figure 3). The reduced NO production represented by the decreased nitrite 
contents in the injured muscle (Figure 2A) led to the induction of ROS production and 
subsequent rhabdomyolysis, but this was blocked only by CS+DEX-5.0 group as early as 3 
hours after reperfusion (Figure 2B). 
 
Genomic effects of DEX on the expression levels of anti- and pro-inflammatory 
cytokines 
  We observed significant increases in the plasma levels of IL-6 and IL-10 in the CS control 
rats (Figures 3A and B), which started at three hours after reperfusion following a transient 
increase in ROS production in the injured muscle (Figure 2B). The increase lasted throughout 
the 24-hour experimental period. DEX dose-dependently reduced the CS-induced plasma 
levels of these cytokines, particularly in the late phase of the 24-hour experimental period 
(Figures 3A and B).  
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 Effects of DEX on the myeloperoxidase activities in muscle, lung, and kidney  
We determined the MPO activities in injured muscle, lung, and kidney tissue. The MPO 
activities in these organs were found to remarkably increase, especially at three hours after 
reperfusion, and they lasted for the entire 24-hour experimental period. However, DEX 
dose-dependently inhibited the MPO activities in the muscle, lungs, and kidneys (Figures 
4A-C).  
 
Effects of DEX on the histological findings of the gastrocnemius muscle, lungs, and 
kidneys 
We next examined the histology of CS-induced damages in the muscle, lung and kidney. In 
comparison with sham rats, the histological changes appeared to be marked in CS rats, and 
dose-dependently improved by DEX treatment in these tissues (SDC Figures 4-6). 
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DISCUSSION 
An important finding of the present study is the significantly reduced nitrite content 
observed in muscle after ischemia (0 h after reperfusion, Figure 2A). During ischemia, the 
basal nitrite content in muscle is reduced because of the decreased NOS activity and 
increased nitrite consumption by enzymatic and non-enzymatic anaerobic bioconversion to 
NO
11-14
, and more prolonged ischemia results in the loss of NO bioavailability and also
impairs the integrity of the muscle cell membranes, thus rendering them more labile to 
oxidative stress upon reperfusion. The most important initial event in I/R injury is the 
excessive production of ROS by nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, xanthine oxidase, mitochondrial respiratory chain complexes, and even uncoupled 
eNOS following reperfusion
4,15
. The ROS thus produced destroy cell membranes as a result
of lipid peroxidation and impair the sarcoplasmic reticulum with massive intracellular 
calcium overload, thus leading to the opening of the mitochondrial permeability transition 
pore, and subsequently inducing cell apoptosis and/or necrosis. The mechanism of 
cytoprotection against I/R injury by NO has been well demonstrated
16-20
 to be through a
reduction of the ROS-mediated cell damage upon reperfusion
21,22
. However, it was unclear
precisely how DEX induced endogenous NO in the present study. In this study, only 
CS+DEX-5.0 group enhanced the muscle nitrite content as rapidly as one hour after 
reperfusion (Figure 2A) by activating eNOS through a dose-dependent sequential 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16 
 
phosphorylation of the PI3K-Akt-eNOS signaling pathway (Figure 1A-C)
22
. However, the 
tissue levels of nitrite might be an indirect marker for endogenous NO production, because 
the reaction of NO with oxygen to form nitrite is kinetically unfavorable compared with the 
reaction of NO with heme proteins, such as hemoglobin and myoglobin, which favorably 
yield nitrate instead under physiological conditions. On the other hand, NOS-derived NO has 
been reported to be predominantly oxidized to nitrite by ceruloplasmin, which is upregulated 
under ischemic conditions
23
. It is therefore possible that the increase in muscle nitrite 
observed in the present study might be due to either enhanced NO production by DEX and/or 
a tendency of NO to be oxidized to nitrite in the early phase of the I/R injury (Figure 2A). 
Either way, these results suggest that the early temporary recovery of the NO stores to 
increase the NO bioavailability may contribute to the DEX-mediated reduction of I/R injury. 
In fact, these DEX-activated NO signaling pathways have been well established to have a 
protective effect against the early phase of I/R injury in other organs, including the 
myocardium
5
 and cerebrum
6
. In line with these observations, we recently reported that the 
treatment of CS rats with intravenous nitrite before reperfusion enhanced the muscle levels of 
nitrite, which was associated with reduced rhabdomyolysis and systemic inflammation, with 
a remarkable improvement in the survival rates
3
. These results clearly indicate that the tissue 
NO-releasing capacity in the early phase of reperfusion plays an important role in modulating 
the process of serious I/R injury.  
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In addition to the local non-genomic signaling mediated by DEX (as discussed above), 
DEX also exerts its anti-inflammatory actions at the transcriptional level via the genomic 
pathway by either direct or indirect interactions with transcription factors, such as NF-kB and 
activator protein-1
24
. While ROS are well known to activate these redox-sensitive 
transcription factors, DEX can inhibit them and the subsequent induction of 
pro-inflammatory mediators, such as IL-6. The plasma level of IL-6 is a clinically relevant 
and feasible parameter to estimate the severity of injury and make a prognosis after 
trauma
25,26
. Furthermore, IL-6 induces the immediate-early gene encoding intercellular 
adhesion molecule-1 after I/R injury
27,28
. Therefore, an enhanced level of IL-6 reflects 
abnormal interactions between the vascular endothelium and circulating leukocytes, which 
was observed in this study as enhanced MPO activities indicative of systemic inflammation 
and multiple organ failure. The present study clearly showed DEX to have dose-dependent 
inhibitory effects on the pro-inflammatory mediators and MPO activities, possibly through a 
transrepression-mediated pathway, which attenuated the systemic inflammation and 
prevented the occurrence of lethal remote organ failure (Figure 4). 
On the other hand, IL-10 is an anti-inflammatory cytokine known to be induced by 
glucocorticoids via the genomic pathway (transactivation), and it is capable of inhibiting the 
production of pro-inflammatory mediators, such as TNF-α and IL-6(Figure 3A). However, 
the effect of glucocorticoid on the plasma levels of IL-10 still remains controversial, as it has 
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been reported to have the opposite effect or to be biphasic, depending on the type of stimulus, 
the dose of glucocorticoid, and the study setting (in vivo or in vitro)
29
. Although further 
studies will be required to delineate this complicated issue, the present study showed the 
increased plasma levels of IL-10 following I/R injury, possibly reflecting a response to 
systemic inflammation and the suppressive effect of DEX on local and systemic 
inflammation could result in decreased plasma levels of IL-10 (Figure 3B).  
In summary, the data presented herein provide evidence that high-dose DEX inhibited the 
I/R-induced local and systemic inflammation at multiple levels of the inflammatory processes, 
and consequently led to a complete recovery from lethal experimental CS. We therefore 
recommend that this treatment should be implemented in clinical situations, particularly in 
combination with the current conventional therapies, including early fluid resuscitation, the 
correction of acidosis, and hemodialysis
1,33-32
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Figure Legends 
 
Figure 1: DEX-induced NO production through the non-genomic signaling pathway. 
The non-genomic effect of DEX on the PI3K-Akt-eNOS signaling pathway in the 
injured muscles. The lower panels show Western blots of each signaling protein (data are 
representative of three independent experiments). The band intensities were quantified by 
densitometry, and the ratios of the levels of phosphorylated to total protein were determined: 
P-p85 to p85 (A), P-Akt to Akt (B), P-eNOS to eNOS (C), White bar: sham, black bar: CS 
control, gray bar: CS+DEX-0.1, shaded bar: CS+DEX-5.0 groups, respectively. Values are 
shown as the means ± SEM. n=3 per group. *: p<0.05 vs. CS control group, #: p<0.05 vs. 
sham group, by a one-way analysis of variance (ANOVA) followed by the Tukey-Kramer 
test. 
 
Figure 2: Effects of DEX on the nitrite levels and ROS production in the injured 
muscles. 
Effects of DEX on the nitrite levels in the injured muscles (A), the effects of DEX on the 
ROS production in the injured muscles, that the ROS levels were determined by measuring 
the TBARS (B) of sham, CS control, CS+DEX-0.1, and CS+DEX-5.0 groups.. White bar: 
sham, black bar: CS control, gray bar: CS+DEX-0.1, shaded bar: CS+DEX-5.0 groups, 
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respectively. Values are shown as the means ± SEM. n=3 per group.*: p<0.05 vs. CS control 
group, **: p<0.01 vs. CS control group, #: p<0.05 vs. sham group, ##: p<0.01 vs. sham 
group, by a one-way analysis of variance (ANOVA) followed by the Tukey-Kramer test. 
 
Figure 3: Effect of DEX on the expression levels of anti- and pro-inflammatory 
cytokines. 
Plasma IL-6 levels (A), plasma IL-10 levels (B) of sham, CS control, CS+DEX-0.1, and 
CS+DEX-5.0 groups. White bar: sham, black bar: CS control, gray bar: CS+DEX-0.1, shaded 
bar: CS+DEX-5.0 groups, respectively. Values are shown as the means ± SEM. n=3 per group. 
*: p<0.05 vs. CS control group, **: p<0.01 vs. CS control group, ##: p<0.01 vs. sham 
group,†: p<0.05 vs. CS+DEX-0.1 group, ††: p<0.01 vs. CS+DEX-0.1 group by a one-way 
analysis of variance (ANOVA) followed by the Tukey-Kramer test. 
 
Figure 4:  Effects of DEX on the MPO activities in muscle, lung and kidney tissues. 
MPO activities of the muscles (A), lungs (B), and kidneys (C) of sham, CS control, 
CS+DEX-0.1, and CS+DEX-5.0 groups. White bar: sham, black bar: CS control, gray bar: 
CS+DEX-0.1, shaded bar: CS+DEX-5.0 groups, respectively. The values are shown as the 
means ± SEM with n=3 per group. *: p<0.05 vs. CS control group, **: p<0.01 vs. CS control 
group, #: p<0.05 vs. sham group, ##: p<0.01 vs. sham group,†: p<0.05 vs. CS+DEX-0.1 
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group, ††: p<0.01 vs. CS+DEX-0.1 group by a one-way analysis of variance (ANOVA) 
followed by the Tukey-Kramer test. 
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Supplemental Digital Content (SDC) 
Acute lethal crush-injured rats can be successfully rescued by a single injection of 
high-dose dexamethasone through a pathway involving PI3K-Akt-eNOS signaling 
Running title: The Effects of Dexamethasone on Crush Syndrome 
Isamu Murata, PhD, Kazuya Ooi, PhD, Shingo Shoji, MS, Yohei Motohashi, BS, Miwa Kan, 
BS, Kazuo Ohtake, PhD, Soichiro Kimura, PhD, Hideo Ueda, PhD, Genya Nakano, MS, 
Kunihiro Sonoda, MS, Yutaka Inoue, PhD, Hiroyuki Uchida, PhD, Ikuo Kanamoto, PhD, 
Yasunori Morimoto PhD, and Jun Kobayashi, MD, PhD 
SDC Method 1: Experimental design 
On reperfusion following ischemia, the vascular endothelium becomes swollen and the 
vessel lumens are plugged and packed with erythrocytes, leukocytes, and platelets, resulting 
in the occurrence of a no-reflow phenomenon 
1
. However, if the duration of ischemia is not
long enough to cause no-reflow phenomenon, cytosolic toxic mediators including myoglobin 
derived from lysed skeletal muscle cells are released to the circulation following reflow 
phenomenon, leading to systemic inflammations with high mortality. However, the shorter 
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ischemia duration (less than 4 hours in this model) is, the less cell damages are, resulting in 
less systemic inflammations with low mortality. We previously reported that a 5-hour 
bilateral hindlimb ischemia exhibited the highest mortality rate (75%) at 24 hours after 
reperfusion compared with other durations of ischemia (0% mortality in less than 4-hour 
ischemia and only 10% mortality in more than 6-hour ischemia) 
2
, thereby providing a critical 
time window to cause reflow and rhabdomyolysis leading to serious CS.  
Based on these reports, a 5-hour compression by the tourniquet was chosen for the crush 
interval in the current study 
2,3
 which provides a more practical animal model closely similar 
to lethal human CS than other animal models. 
 
SDC Method 2: Histology 
All sections from tissues were scored by a blinded observer according to the 
semiquantitative histological scoring systems of skeletal muscle, lung and kidney described 
in the previous reports 
4,5,6
.  
 
SDC Table 1 and 2 :  Effects of the conventional therapies on plasma biochemical 
markers, mean arterial pressure and blood gas of CS rat 
CS control rats showed significant increases in the markers of rhabdomyolysis, such as 
CPK, K
+
, and LDH in the plasma as early as one hour after reperfusion. CS control rats also 
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showed a significantly decreased MAP throughout the 24-hour experimental period, which 
consequently induced metabolic acidosis shown in the arterial blood gas analysis (pH, base 
excess, HCO3
-
 and lactate). However, fluid resuscitation (30mL/kg/hr
7,8
, starting immediately
after reperfusion for 3 hours) of saline or bicarbonated Ringer's solution (BICARBON
○R
), 
significantly suppressed rhabdomyolysis and subsequent hypovolemic hypotension (SDC 
Table 2). The circulatory improvement also decreased the plasma levels of renal damage 
markers (creatinine and BUN, SDC Table 1). These beneficial effects were more observed in 
the bicarbonated Ringer's solution than saline (SDC Table 1 and 2). 
SDC Figure 1:  Effects of dexamethasone on the survival rate of CS rat. 
The survival rates among the four groups from 0 to 48 h after reperfusion. Open circle: 
sham (n=10), closed circle: CS control (n=29), open diamond: CS+DEX-0.1(n=14), closed 
diamond: CS+DEX-5.0 groups (n=10), respectively. DEX treatment showed dose-dependent 
improvement of survival rates from 24% (CS control group) to 24% (CS+DEX-0.1 group) 
and 100% (CS+DEX-5.0 groups) after a 48 h experimental period. **: p<0.01 vs. CS control 
group, ††: p<0.01 vs. CS+DEX-0.1 group. Survival curves were calculated by the 
Kaplan-Meier method and compared by a log-rank test. 
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SDC Figure 2:  Effects of the conventional therapies on the survival rate of CS rat. 
 The survival rates among the four groups treated with or without conventional therapies  
from 0 to 48 h after reperfusion. Open circle: sham (n=10), closed circle: CS control (n=29), 
open square: CS+saline (n=10), closed square: CS+BICARBON
○R
 groups (n=10). Aggressive 
saline resuscitation showed a high survival rate (90%) until 6 hours after reperfusion, 
although it ultimately ended in failure 48 hours after reperfusion with a final mortality rate 
(30%) similar to the CS control group. CS+BICARBON
○R
 group showed a higher survival 
rate (60%) at 48-hour experimental period, however it does not appear nearly so good as the 
high-dose DEX-treated group. #: p<0.01 vs. CS control group. Survival curves were 
calculated by the Kaplan-Meier method and compared by a log-rank test. 
 
SDC Figure 3:  Effects of DEX on the total eNOS expression in the injured muscles. 
The ratio of protein levels of eNOS to α-tubuline. The ratios are all represented by 
arbitrary units. The lower panels show Western blots of eNOS and α-tubuline in four groups 
at each experimental period (data are representative of three independent experiments). White 
bar: sham, black bar: CS control, gray bar: CS+DEX-0.1, shaded bar: CS+DEX-5.0 groups, 
respectively. The values are shown as the means ± SEM with n=3 per group. These result 
calculated by a one-way analysis of variance (ANOVA) followed by the Tukey-Kramer test 
(not significant). 
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SDC Figure 4:  Effects of DEX on the histological findings in the gastrocnemius 
muscle. 
In comparison with sham (a), the gastrocnemius muscles of the CS control rats showed 
degenerated and atrophic muscle fibers with significant edema and a mild dilation of the 
interstitial vessels (b). These findings were much less pronounced in the low-dose DEX (c), 
and were largely abrogated in the high-dose DEX (d). Hematoxylin-eosin staining of the 
gastrocnemius muscles of sham (A), CS control (B), CS+DEX-0.1 (C), and CS+DEX-5.0 
groups (D), respectively. Microscopic photos are representative of 3 independent experiments 
(×200, scale bars=100 μm). 
SDC Figure 5:  Effects of DEX on the histological findings in the lung. 
The most remarkable pathological features were found in the lungs, which showed 
prominent intra-alveolar and interstitial edema in the CS control rats (f) in comparison with 
the normal alveolar wall with a thin alveolar septum in the sham-injured rats (e). These 
pathological changes were dose-dependently improved by DEX (g and h). Hematoxylin-eosin 
staining of the lung of sham (A), CS control (B), CS+DEX-0.1 (C), and CS+DEX-5.0 groups 
(D), respectively. Microscopic photos are representative of 3 independent experiments (×200, 
scale bars=100 μm). 
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SDC Figure 6:  Effects of DEX on the histological findings in the kidney. 
The cortex of the kidneys of the CS control rats exhibited a moderate dilation of the distal 
tubules and a flattening of epithelial cells due to acute renal failure in comparison with the 
sham-injured rats (i and j). DEX also improved these pathological changes (k and l). 
Hematoxylin-eosin staining of the kidney of sham (A), CS control (B), CS+DEX-0.1 (C), and 
CS+DEX-5.0 groups (D), respectively. Microscopic photos are representative of 3 
independent experiments (×200, scale bars=100 μm). 
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Table 1 Effects of I/R injury and DEX on plasma biochemical markers 
Time after reperfusion (h) 1 3 6 24 
K
+
(mEq/L) 
sham 4.2 ± 0.1 3.9 ± 0.1 3.7 ± 0.1 3.9 ± 0.1 
CS control 7.3 ± 0.2 
## 
8.9 ± 0.1 
## 
9.2 ± 0.5 
## 
6.6 ± 0.5 
## 
Dex-0.1 6.4 ± 0.3 7.6 ± 0.1 6.5 ± 0.3 
** 
5.9 ± 1.0 
Dex-5.0 6.1 ± 0.2 6.4 ± 0.2 
** 
6.5 ± 0.3 
** 
4.3 ± 0.4 
** 
BUN 
(mg/dL) 
sham 13.3 ± 2.2 13.5 ± 1.3 11.7 ± 0.9 20.4 ± 1.2 
CS control 24.8 ± 0.5 41.3 ± 3.7 
## 
56.6 ± 2.1 
## 
37.0 ± 1.6 
## 
CS+Dex-0.1 25.4 ± 1.4 40.0 ± 4.3 51.6 ± 4.0 24.2 ± 2.1 
* 
CS+Dex-5.0 23.0 ± 2.0 39.8 ± 1.3 49.1 ± 3.4 27.0 ± 1.2 
* 
creatinine 
(mg/dL) 
sham 0.16 ± 0.01 0.17 ± 0.02 0.20 ± 0.01 0.24 ± 0.01 
CS control 0.30 ± 0.05 1.51 ± 0.33 
## 
0.79 ± 0.07 
## 
0.53 ± 0.05 
# 
CS+Dex-0.1 0.20 ± 0.01 0.37 ± 0.01 
** 
0.27 ± 0.04 
** 
0.24 ± 0.03 
CS+Dex-5.0 0.20 ± 0.01 0.31 ± 0.03 
** 
0.27 ± 0.03 
** 
0.21 ± 0.02 
CPK 
(IU/L) 
sham 1371 ± 244 1034 ± 218 322 ± 81 121 ± 13 
CS control 21,220 ± 2,229 
## 
24,320 ± 1,930 
## 
23,187 ± 1,494 
## 
15,240 ± 1,335 
## 
CS+Dex-0.1 8,960 ± 1,620 
** 
24,867 ± 3,351 26,080 ± 4,688 7,593 ± 1,902 
CS+Dex-5.0 8,893 ± 924 
** 
18,227 ± 2,715 
* 
14,487 ± 2,517 
* 
5,743 ± 322 
* 
LDH 
(IU/L) 
sham 224 ± 32 309 ± 18 181 ± 20 69 ± 7 
CS control 1,860 ± 57 
# 
3,190 ± 650 
## 
3,466 ± 198 
## 
3,633 ± 583 
## 
CS+Dex-0.1 739 ± 99 2,488 ± 420 2,603 ± 539 3,717 ± 666 
CS+Dex-5.0 679 ± 94 2,009 ± 301 2,328 ± 301 
* 
2,324 ± 214 
* 
Values are shown as the means ± SEM. n= 3 per group. #: p<0.05 vs. sham group, ##: p<0.01 vs. sham group, *: p<0.05 vs. CS control group, 
**: p<0.01 vs. CS control group by a one-way analysis of variance (ANOVA) followed by the Tukey-Kramer test. 
Tables
Values are shown as the means ± SEM. n= 3 per group. #: p<0.05 vs. sham group, ##: p<0.01 vs. sham group, *: p<0.05 vs. CS control group, 
**: p<0.01 vs. CS control group, †: p<0.05 vs. CS+DEX-0.1 group, ††: p<0.01 vs. CS+DEX-0.1 group by a one-way analysis of variance 
(ANOVA) followed by the Tukey-Kramer test. 
Table 2 Effects of I/R injury and DEX on MAP and arterial blood gas analysis. 
Time after reperfusion (h) 1 3 6 24 
MAP 
(mmHg) 
sham 121.3 ± 5.8 116.7 ± 4.7 111.9 ± 7.3 118.1 ± 2.7 
CS control 79.6 ± 1.5 
## 
67.4 ± 2.3 
## 
54.7 ± 3.0 
## 
59.7 ± 3.5 
## 
CS+Dex-0.1 88.8 ± 2.5 80.5 ± 4.9 76.0 ± 1.7 
* 
72.1 ± 1.4 
CS+Dex-5.0 84.3 ± 5.1 86.1 ± 0.4 
* 
84.6 ± 3.4 
** 
100.3 ± 1.5 
**,†† 
pH 
sham 7.42 ± 0.01 7.44 ± 0.00 7.47 ± 0.01 7.42 ± 0.02 
CS control 7.37 ± 0.01 7.33 ± 0.01 
# 
7.29 ± 0.03 
## 
7.28 ± 0.02 
## 
CS+Dex-0.1 7.35 ± 0.03 7.33 ± 0.01 7.28 ± 0.02 7.30 ± 0.01 
CS+Dex-5.0 7.41 ± 0.03 7.35 ± 0.04 7.36 ± 0.04 
* 
7.38 ± 0.02 
* 
HCO3
- 
(mEq/L) 
sham 27.3 ± 0.3 27.3 ± 0.3 30.0 ± 0.4 27.0 ± 1.2 
CS control 19.9 ± 1.3 
## 
19.3 ± 0.3 
## 
16.0 ± 0.6 
## 
15.7 ± 0.3 
## 
CS+Dex-0.1 24.2 ± 0.7 
** 
21.1 ± 0.2 19.9 ± 0.8 
* 
21.0 ± 1.1 
** 
CS+Dex-5.0 26.8 ± 0.6 
** 
25.0 ± 0.4 
**,† 
23.8 ± 0.8 
**.† 
25.4 ± 0.5 
**.†† 
base 
excess 
(mmol/L) 
sham 3.0 ± 0.6 3.0 ± 0.6 3.6 ± 0.9 1.3 ± 0.3 
CS control -5.0 ± 0.8 
## 
-7.0 ± 0.6 
## 
-9.7 ± 0.9 
## 
-6.7 ± 1.2 
## 
CS+Dex-0.1 -0.3 ± 1.2 
* 
-4.7 ± 0.3 -6.0 ± 0.0 -1.3 ± 0.9 
** 
CS+Dex-5.0 2.0 ± 0.6 
** 
1.0 ± 1.2 
**,† 
-1.7 ± 1.5 
**,† 
2.0 ± 0.6 
** 
Lactate 
(mmol/L) 
sham 1.3 ± 0.1 1.1 ± 0.1 1.1 ± 0.3 0.8 ± 0.1 
CS control 1.5 ± 0.1 1.1 ± 0.1 2.3 ± 0.1 
## 
2.9 ± 0.3 
## 
CS+Dex-0.1 1.1 ± 0.2 1.2 ± 0.1 1.5 ± 0.1 1.5 ± 0.3 
* 
CS+Dex-5.0 1.1 ± 0.3 1.2 ± 0.1 1.3 ± 0.2 
* 
0.6 ± 0.2 
** 
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